Compare STRIDES PHARMA SCIENCE with Biocon - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs BIOCON - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE BIOCON STRIDES PHARMA SCIENCE/
BIOCON
 
P/E (TTM) x 43.3 31.5 137.7% View Chart
P/BV x 2.0 3.7 54.0% View Chart
Dividend Yield % 0.2 0.3 91.6%  

Financials

 STRIDES PHARMA SCIENCE   BIOCON
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
BIOCON
Mar-19
STRIDES PHARMA SCIENCE/
BIOCON
5-Yr Chart
Click to enlarge
High Rs1,147707 162.2%   
Low Rs642554 115.9%   
Sales per share (Unadj.) Rs317.291.9 345.2%  
Earnings per share (Unadj.) Rs7.816.7 46.9%  
Cash flow per share (Unadj.) Rs25.124.2 103.7%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.20.2 141.0%  
Book value per share (Unadj.) Rs274.3101.6 269.8%  
Shares outstanding (eoy) m89.50600.00 14.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.86.9 41.1%   
Avg P/E ratio x114.037.7 302.2%  
P/CF ratio (eoy) x35.726.1 136.9%  
Price / Book Value ratio x3.36.2 52.6%  
Dividend payout %25.56.0 426.0%   
Avg Mkt Cap Rs m80,058378,330 21.2%   
No. of employees `0002.56.1 40.9%   
Total wages/salary Rs m4,34111,653 37.2%   
Avg. sales/employee Rs Th11,325.88,994.3 125.9%   
Avg. wages/employee Rs Th1,731.41,900.7 91.1%   
Avg. net profit/employee Rs Th280.11,635.3 17.1%   
INCOME DATA
Net Sales Rs m28,39455,144 51.5%  
Other income Rs m9411,444 65.1%   
Total revenues Rs m29,33456,588 51.8%   
Gross profit Rs m3,96515,883 25.0%  
Depreciation Rs m1,5404,478 34.4%   
Interest Rs m1,962709 276.8%   
Profit before tax Rs m1,40312,140 11.6%   
Minority Interest Rs m09 0.0%   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m972,123 4.6%   
Profit after tax Rs m70210,026 7.0%  
Gross profit margin %14.028.8 48.5%  
Effective tax rate %6.917.5 39.7%   
Net profit margin %2.518.2 13.6%  
BALANCE SHEET DATA
Current assets Rs m24,83648,228 51.5%   
Current liabilities Rs m18,99330,376 62.5%   
Net working cap to sales %20.632.4 63.6%  
Current ratio x1.31.6 82.4%  
Inventory Days Days7168 103.9%  
Debtors Days Days11386 132.6%  
Net fixed assets Rs m34,28964,130 53.5%   
Share capital Rs m8953,000 29.8%   
"Free" reserves Rs m23,65157,980 40.8%   
Net worth Rs m24,54660,980 40.3%   
Long term debt Rs m15,51315,766 98.4%   
Total assets Rs m65,437121,924 53.7%  
Interest coverage x1.718.1 9.5%   
Debt to equity ratio x0.60.3 244.5%  
Sales to assets ratio x0.40.5 95.9%   
Return on assets %4.18.8 46.2%  
Return on equity %2.916.4 17.4%  
Return on capital %6.916.8 41.2%  
Exports to sales %028.1 0.0%   
Imports to sales %018.9 0.0%   
Exports (fob) Rs mNA15,506 0.0%   
Imports (cif) Rs mNA10,399 0.0%   
Fx inflow Rs m15,69715,506 101.2%   
Fx outflow Rs m73510,399 7.1%   
Net fx Rs m14,9625,107 293.0%   
CASH FLOW
From Operations Rs m1,87111,546 16.2%  
From Investments Rs m5,826-7,138 -81.6%  
From Financial Activity Rs m-10,157-2,417 420.2%  
Net Cashflow Rs m-2,6152,103 -124.3%  

Share Holding

Indian Promoters % 27.7 40.4 68.6%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 37.8 8.4 450.0%  
FIIs % 8.6 10.7 80.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 19.9 130.2%  
Shareholders   56,241 109,995 51.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   PROCTER & GAMBLE HEALTH  STERLING BIOTECH  ASTRAZENECA PHARMA  SUN PHARMA  IPCA LABS  

Compare STRIDES PHARMA SCIENCE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


May 7, 2021 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE - DISHMAN PHARMA COMPARISON

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS